| Literature DB >> 31684183 |
Pedro Acosta-Manzano1,2, Irene Coll-Risco3,4, Mireille N M Van Poppel5, Víctor Segura-Jiménez6,7, Pedro Femia8, Lidia Romero-Gallardo9,10, Milkana Borges-Cosic11,12, Javier Díaz-Castro13, Jorge Moreno-Fernández14, Julio J Ochoa-Herrera15, Virginia A Aparicio16,17.
Abstract
The aim of the present study was to analyze the influence of a supervised concurrent exercise-training program, from the 17th gestational week until delivery, on cytokines in maternal (at 17th and 35th gestational week, and at delivery) and arterial and venous cord serum. Fifty-eight Caucasian pregnant women (age: 33.5 ± 4.7 years old, body mass index: 23.6 ± 4.1kg/m2) from the GESTAFIT Project (exercise (n = 37) and control (n = 21) groups) participated in this quasi-experimental study (per-protocol basis). The exercise group followed a 60-min 3 days/week concurrent (aerobic-resistance) exercise-training from the 17th gestational week to delivery. Maternal and arterial and venous cord serum cytokines (fractalkine, interleukin (IL)-1β, IL-6, IL-8, IL-10, interferon (IFN)-γ, and tumor necrosis factor (TNF)-α) were assessed using Luminex xMAP technology. In maternal serum (after adjusting for the baseline values of cytokines), the exercise group decreased TNF-α (from baseline to 35th week, p = 0.02), and increased less IL-1β (from baseline to delivery, p = 0.03) concentrations than controls. When adjusting for other potential confounders, these differences became non-significant. In cord blood, the exercise group showed reduced arterial IL-6 and venous TNF-α (p = 0.03 and p = 0.001, respectively) and higher concentrations of arterial IL-1β (p = 0.03) compared to controls. The application of concurrent exercise-training programs could be a strategy to modulate immune responses in pregnant women and their fetuses. However, future research is needed to better understand the origin and clearance of these cytokines, their role in the maternal-placental-fetus crosstalk, and the influence of exercise interventions on them.Entities:
Keywords: cytokines; immune; interferon-gamma; interleukin 1B; interleukin 6; tumor necrosis factor
Year: 2019 PMID: 31684183 PMCID: PMC6912691 DOI: 10.3390/jcm8111862
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Sociodemographic and clinical characteristics of pregnant women (n = 48).
| Total | Control | Intervention | |||||
|---|---|---|---|---|---|---|---|
|
| 33.5 | (4.7) | 33.5 | (4.7) | 33.5 | (4.8) | 0.97 |
|
| 16.8 | (1.4) | 16.9 | (1.1) | 16.6 | (1.7) | 0.68 |
|
| 33.0 | (1.7) | 32.1 | (1.7) | 31.6 | (1.7) | 0.28 |
|
| 39.4 | (1.4) | 39.1 | (1.6) | 39.8 | (1) | 0.16 |
|
| 83.9 | (8.2) | |||||
|
| |||||||
| Living alone | 0 | (0) | 0 | (0) | 0 | (0) | |
| Living with partner | 48 | (100) | 28 | (100) | 20 | (100) | |
|
| |||||||
| Non-university degree | 20 | (41.7) | 11 | (39.3) | 9 | (45) | 0.92 |
| University degree | 28 | (58.3) | 17 | (60.7) | 11 | (55) | |
|
| |||||||
| Work full/part time | 31 | (64.6) | 21 | (75) | 10 | (50) | 0.14 |
| Unemployed/Retired/Housekeeper | 17 | (35.4) | 7 | (25) | 10 | (50) | |
|
| |||||||
| Primarious | 28 | (58.3) | 14 | (50) | 14 | (70) | 0.28 |
| Multiparious | 20 | (41.7) | 14 | (50) | 6 | (30) | |
|
| 0.5 | (0.8) | 0.5 | (0.8) | 0.5 | (0.8) | 0.64 |
|
| |||||||
| Spontaneous | 27 | (57.4) | 16 | (59.3) | 11 | (55) | 0.20 |
| Vacuum extraction | 9 | (19.1) | 3 | (11.1) | 6 | (30) | |
| Caesarean section | 11 | (23.4) | 8 | (29.6) | 3 | (15) | |
|
| |||||||
| Male | 24 | (52.2) | 13 | (50) | 11 | (55) | 0.97 |
| Female | 22 | (47.8) | 13 | (50) | 9 | (45) | |
|
| 23.2 | (3.8) | 22.8 | (3.5) | 24.0 | (4.4) | 0.32 |
|
| 23.6 | (4.1) | 23.3 | (3.5) | 24.0 | (4.9) | 0.98 |
|
| 1.1 | (2.8) | 1.1 | (3.2) | 0.9 | (2) | 0.81 |
|
| 9.5 | (3.2) | 10.1 | (2.8) | 8.7 | (3.5) | 0.234 |
|
| |||||||
| Systolic blood pressure (mmHg) | 105.2 | (8.8) | 106.1 | (9.1) | 103.8 | (8.4) | 0.38 |
| Diastolic blood pressure (mmHg) | 61.9 | (7.5) | 61.5 | (7.9) | 62.4 | (7) | 0.70 |
| Resting heart rate (bpm) | 81.7 | (10.8) | 81.9 | (10.7) | 81.5 | (11.3) | 0.57 |
|
| 0.4 | (1.6) | 0.5 | (2) | 0.2 | (0.9) | 0.50 |
|
| 29.1 | (3.8) | 29.3 | (3.9) | 28.8 | (3.9) | 0.73 |
|
| |||||||
| Sedentary time (min/day) | 503.9 | (98.5) | 486.0 | (116.5) | 526.4 | (65.7) | 0.19 |
| Light PA (min/day) | 392.5 | (89.9) | 420.8 | (99.2) | 356.7 | (61.9) |
|
| Moderate-vigorous PA (min/day) | 37.8 | (23) | 37.2 | (26.1) | 38.6 | (19.0) | 0.48 |
| Bouted moderate-vigorous PA (min/week) | 99.4 | (120.1) | 106.1 | (141.6) | 90.8 | (89.1) | 0.95 |
| Total PA (min/day) | 430.3 | (93.0) | 458.0 | (99.1) | 395.3 | (73.0) |
|
| Average accelerometer wear time (min/day) | 934.2 | (53.5) | 944.0 | (61.5) | 921.7 | (39.3) | 0.18 |
| Relative percentage of daily sedentary time (%) | 53.9 | (9.7) | 51.3 | (10.7) | 57.2 | (7.4) |
|
| Relative percentage of total daily PA (%) | 46.1 | (9.7) | 48.7 | (10.7) | 42.8 | (7.4) |
|
PA, physical activity. Continuous variables are presented as mean (standard deviation) and categorical variables as number (percentage). Superscripts in outcomes indicate lower sample size when considering all participants: a n = 47, b n = 46, c n = 45, d n = 43, e n = 41. P values were calculated using independent sample Student’s t-test (normal distribution, homoscedasticity), Welch´s test (normal distribution, heteroscedasticity) and Mann–Whitney U test (non-normal distribution) for continuous variables, and the Chi-square test for categorical variables.
Cytokines concentrations at the three time points (n = 48).
| Cytokines | 17th Week of Gestation ( | 35th Week of Gestation ( | Delivery ( | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Control ( | Intervention ( | Control ( | Intervention ( | Control ( | Intervention ( | ||||||||||
| Maternal Serum | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | |||
| Fractalkine (pg/mL) | 376.1 | 149.0 | 371.4 | 152.7 | 0.85 | 375.8 | 107.3 | 391.4 | 107.2 | 0.74 | 345.5 | 64.6 | 387.2 | 109.6 | 0.17 |
| Interleukin 1 beta (pg/mL) | 6.8 | 2.6 | 6.1 | 3.2 | 0.17 | 7.5 | 3.0 | 6.3 | 3.6 | 0.20 | 9.6 | 3.9 | 7.2 | 3.5 | 0.06 |
| Interleukin 6 (pg/mL) | 5.6 | 2.8 | 5.9 | 3.0 | 0.70 | 6.3 | 2.5 | 5.2 | 2.6 | 0.15 | 32.9 | 9.5 | 33.2 | 19.1 | 0.95 |
| Interleukin 8 (pg/mL) | 21.5 | 10.7 | 18.6 | 7.6 | 0.50 | 19.8 | 8.5 | 21.6 | 10.7 | 0.62 | 34.4 | 6.8 | 37.8 | 15.2 | 0.39 |
| Interleukin 10 (pg/mL) | 24.0 | 9.6 | 22.3 | 12.2 | 0.59 | 24.5 | 8.8 | 29.1 | 9.8 | 0.10 | 40.7 | 11.0 | 50.4 | 16.7 |
|
| Interferon gamma (pg/mL) | 23.5 | 11.0 | 22.6 | 12.8 | 0.57 | 22.9 | 11.5 | 18.4 | 9.3 | 0.15 | 18.8 | 6.6 | 15.5 | 7.0 | 0.14 |
| Tumor necrosis factor alpha (pg/mL) | 5.6 | 1.7 | 5.2 | 2.7 | 0.11 | 7.1 | 1.7 | 6.1 | 1.4 |
| 10.1 | 2.7 | 9.0 | 2.6 | 0.25 |
|
| |||||||||||||||
| Fractalkine (pg/mL) | 314.6 | 91.1 | 372.3 | 103.9 | 0.07 | ||||||||||
| Interleukin 1 beta (pg/mL) | 1.2 | 0.9 | 1.5 | 0.5 |
| ||||||||||
| Interleukin 6 (pg/mL) | 18.9 | 5.0 | 15.0 | 4.3 |
| ||||||||||
| Interleukin 8 (pg/mL) | 51.8 | 31.6 | 56.6 | 24.2 | 0.62 | ||||||||||
| Interleukin 10 (pg/mL) | 10.2 | 2.6 | 12.5 | 4.0 | 0.06 | ||||||||||
| Interferon gamma (pg/mL) | 3.2 | 1.5 | 2.6 | 1.1 | 0.15 | ||||||||||
| Tumor necrosis factor-alpha (pg/mL) | 15.8 | 3.5 | 14.3 | 2.9 | 0.17 | ||||||||||
|
| |||||||||||||||
| Fractalkine (pg/mL) | 265.8 | 113.1 | 300.4 | 117.3 | 0.36 | ||||||||||
| Interleukin 1 beta (pg/mL) | 1.4 | 0.8 | 1.7 | 1.0 | 0.58 | ||||||||||
| Interleukin 6 (pg/mL) | 13.3 | 5.4 | 12.6 | 4.8 | 0.65 | ||||||||||
| Interleukin 8 (pg/mL) | 59.1 | 22.8 | 60.8 | 17.4 | 0.80 | ||||||||||
| Interleukin 10 (pg/mL) | 12.9 | 4.1 | 13.3 | 3.8 | 0.78 | ||||||||||
| Interferon gamma (pg/mL) | 2.4 | 1.0 | 2.8 | 1.4 | 0.41 | ||||||||||
| Tumor necrosis factor-alpha (pg/mL) | 19.0 | 5.4 | 13.9 | 3.9 |
| ||||||||||
SD, standard deviation. a indicate lower sample size of the control group (n = 15) in all the umbilical arterial serum inflammatory markers. p values were calculated using independent sample Student’s t-test (normal distribution, homoscedasticity), Welch´s test (normal distribution, heteroscedasticity) and Mann–Whitney U test (non-normal distribution) for continuous variables.
Per-protocol analyses showing the effect of the concurrent exercise-training program on maternal serum cytokines (n = 48).
| Changes in Control Group | Changes in Exercise Group | Model Unadjusted | Model 1 | Model 2 | Adjusted | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | B | SE | β | B | SE | β | B | SE | β | |||||
|
|
|
| |||||||||||||||
| Fractalkine | −0.35 | 101.10 | 19.98 | 91.67 | 20.33 | 28.49 | 0.11 | 0.48 | 17.92 | 20.72 | 0.09 | 0.39 | 15.11 | 23.16 | 0.08 | 0.52 | −0.011 |
| Interleukin 1 beta | 0.67 | 3.13 | 0.17 | 2.12 | −0.50 | 0.81 | −0.09 | 0.54 | −0.79 | 0.76 | −0.14 | 0.31 | −1.17 | 0.82 | −0.22 | 0.16 | −0.013 |
| Interleukin 6 | 0.74 | 3.27 | −0.67 | 3.11 | −1.41 | 0.94 | −0.22 | 0.14 | −1.19 | 0.73 | −0.18 | 0.11 | −1.11 | 0.78 | −0.17 | 0.16 | 0.047 |
| Interleukin 8 | −1.68 | 9.48 | 3.05 | 7.40 | 4.73 | 2.54 | 0.26 | 0.07 | 3.38 | 2.23 | 0.19 | 0.14 | 4.51 | 2.60 | 0.25 | 0.09 | 0.070 |
| Interleukin 10 | 0.55 | 13.74 | 6.80 | 8.88 | 6.25 | 3.50 | 0.25 | 0.08 | 4.66 | 2.47 | 0.19 | 0.07 | 4.39 | 2.66 | 0.18 | 0.11 | 0.044 |
| Interferon gamma | −0.55 | 9.97 | −4.21 | 9.65 | −3.65 | 2.88 | −0.18 | 0.21 | −4.11 | 2.50 | −0.21 | 0.11 | −5.56 | 2.81 | −0.27 | 0.06 | 0.013 |
| Tumor necrosis factor alpha | 1.51 | 2.29 | 0.86 | 2.52 | −0.66 | 0.70 | −0.14 | 0.35 | −1.03 | 0.43 | −0.22 |
| −0.86 | 0.44 | −0.19 | 0.06 | 0.019 |
|
|
|
| |||||||||||||||
| Fractalkine | −3.22 | 69.74 | 4.36 | 101.34 | 7.57 | 28.47 | 0.05 | 0.79 | 24.09 | 20.9 | 0.14 | 0.26 | 26.66 | 22.00 | 0.16 | 0.23 | −0.026 |
| Interleukin 1 beta | 3.24 | 2.86 | 0.86 | 3.78 | −2.38 | 2.10 | −0.34 |
| −2.38 | 1.06 | −0.34 |
| −2.09 | 1.10 | −0.30 | 0.07 | 0.093 |
| Interleukin 6 | 26.91 | 9.86 | 27.06 | 18.93 | 0.15 | 4.92 | 0.01 | 0.98 | 0.23 | 4.97 | 0.01 | 0.96 | −0.90 | 5.2 | −0.03 | 0.86 | −0.029 |
| Interleukin 8 | 14.53 | 14.57 | 19.31 | 16.10 | 4.78 | 5.04 | 0.16 | 0.35 | 3.33 | 3.91 | 0.11 | 0.40 | 3.20 | 4.18 | 0.11 | 0.45 | 0.025 |
| Interleukin 10 | 18.65 | 13.98 | 27.30 | 16.93 | 8.65 | 0.10 | 0.28 | 0.10 | 9.40 | 4.55 | 0.30 |
| 7.92 | 4.37 | 0.25 | 0.08 | 0.076 |
| Interferon gamma | −2.50 | 9.08 | −8.26 | 12.21 | −5.76 | 3.53 | −0.27 | 0.11 | −3.97 | 2.03 | −0.18 | 0.06 | −3.31 | 2.09 | −0.15 | 0.12 | 0.044 |
| Tumor necrosis factor alpha | 4.66 | 2.72 | 3.62 | 2.97 | −1.04 | 0.94 | −0.19 | 0.27 | −1.03 | 085 | −0.18 | 0.23 | −0.83 | 0.87 | −0.15 | 0.35 | 0.007 |
SD, standard deviation; B, unstandardized regression coefficient; SE, standard error; β, standardized regression coefficient. Per-protocol analyses were performed including only women who attended ≥75% of the exercise sessions. Linear regression analyses (enter method) were used to examine the differences in inflammatory markers between the control and exercise group. The within-group post-pre intervention changes (from the exercise training group minus the control group) on cytokine concentrations were included in the linear regression analyses as dependent variables, and the group (control = 0 and exercise = 1) as independent variable. When considering the “35th week-17th week” multiple point analyses, model 1 was adjusted for baseline values of the particular cytokine and adherence to the Mediterranean Diet score; and model 2 was additionally adjusted for the relative percentage of daily total physical activity (total physical activity/accelerometer wearing time). When considering the “delivery-17th week” multiple point analyses, model 1 was adjusted for baseline values of the particular cytokine; and model 2 was additionally adjusted for parity status and gestational age at birth. * The adjusted R values shown are derived from the unadjusted model. All the assumptions related to the generalization of the results have been reasonably met, and non-transformations or data preparation of the outcomes were needed.
Per-protocol analyses showing the effect of the concurrent exercise-training program on arterial and venous cord serum cytokines at delivery (n = 38).
| Model Unadjusted | Model 1 | Model 2 | Adjusted | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B | SE | β | B | SE | β | B | SE | β | |||||
|
| |||||||||||||
| Fractalkine * | 0.63 | 0.32 | 0.33 | 0.06 | 0.53 | 0.32 | 0.28 | 0.11 | 0.52 | 0.33 | 0.27 | 0.13 | 0.081 |
| Interleukin 1 beta * | 0.66 | 0.29 | 0.38 |
| 0.69 | 0.30 | 0.39 |
| 0.72 | 0.27 | 0.41 |
| 0.113 |
| Interleukin 6 * | −0.83 | 0.32 | −0.42 |
| −0.79 | 0.33 | −0.40 |
| −0.80 | 0.34 | −0.40 |
| 0.147 |
| Interleukin 8 | 4.83 | 9.56 | 0.09 | 0.61 | 6.67 | 9.85 | 0.12 | 0.50 | 7.25 | 9.93 | 0.13 | 0.47 | −0.023 |
| Interleukin 10 | 2.32 | 1.20 | 0.32 | 0.06 | 2.14 | 1.24 | 0.30 | 0.10 | 2.14 | 1.23 | 0.30 | 0.09 | 0.076 |
| Interferon gamma | −0.65 | 0.44 | −0.25 | 0.15 | −0.70 | 0.46 | −0.27 | 0.14 | −0.68 | 0.46 | −0.27 | 0.15 | 0.034 |
| Tumor necrosis factor alpha | −1.55 | 1.10 | −0.24 | 0.17 | −1.63 | 1.14 | −0.25 | 0.17 | −1.63 | 1.14 | −0.26 | 0.16 | 0.029 |
|
| |||||||||||||
| Fractalkine | 34.58 | 37.38 | 0.15 | 0.36 | 27.29 | 36.93 | 0.12 | 0.47 | 23.68 | 38.24 | 0.10 | 0.54 | −0.004 |
| Interleukin 1 beta * | 0.21 | 0.32 | 0.11 | 0.53 | 0.18 | 0.33 | 0.10 | 0.58 | 0.17 | 0.33 | 0.09 | 0.62 | 0.011 |
| Interleukin 6 | −0.77 | 1.67 | −0.08 | 0.65 | −0.90 | 1.70 | −0.09 | 0.60 | −1.03 | 1.77 | −0.10 | 0.56 | 0.006 |
| Interleukin 8 * | 0.20 | 0.32 | 0.11 | 0.53 | 0.22 | 0.33 | 0.11 | 0.50 | 0.16 | 0.33 | 0.08 | 0.64 | −0.016 |
| Interleukin 10 | 0.37 | 1.28 | 0.05 | 0.78 | 0.31 | 1.31 | 0.04 | 0.82 | 0.23 | 1.36 | 0.03 | 0.87 | −0.025 |
| Interferon gamma | 0.34 | 0.41 | 0.14 | 0.41 | 0.24 | 0.39 | 0.10 | 0.54 | 0.29 | 0.41 | 0.12 | 0.49 | −0.008 |
| Tumor necrosis factor alpha | −5.07 | 1.54 | −0.48 |
| −5.53 | 1.45 | −0.53 |
| −5.21 | 1.45 | −0.50 |
| 0.211 |
SD, standard deviation; B, unstandardized regression coefficient; SE, standard error; β, standardized regression coefficient. Per-protocol analyses were performed including only women who attended ≥75% of the exercise sessions. Linear regression analyses (enter method) were used to examine the differences in inflammatory markers between the control and exercise group. The umbilical arterial serum cytokine concentrations were included in the linear regression analyses as dependent variables, and the group (control = 0 and exercise = 1) as independent variable. Model 1 was adjusted for adherence to the Mediterranean Diet score and model 2 was additionally adjusted for parity status and gestational age at birth. * Optimum Box-Cox transformations and a subtle variation of winsorizing (convert back from a z-score: replacing extreme scores with a score equivalent to ±2.58 SDs from the mean) were performed on inflammatory markers. a indicate lower sample size of the control group (n = 15) in all umbilical arterial serum inflammatory markers. b the adjusted R2 values shown are derived from the unadjusted model (i.e., it assesses the individual influence of the exercise intervention without confounders). All the assumptions related to the generalization of the results have been reasonably met. After dealing with the problematic outcomes, the results remained similar (but with better and more symmetrical distribution of data) to the analyses without data preparation, excepting for the interleukin 1 beta which became statically significant.
Figure 1Flowchart of pregnant women through each stage of the study.